Advertisement
Screener

REGENERON PHARMACEUTICALS, INC. (REGN) Cash Flow Breakdown

2.8 / 5 stars · 68/120 Roast Me

REGENERON PHARMACEUTICALS, INC. Cash Flow Breakdown

Cash flow breakdown shows where REGENERON PHARMACEUTICALS, INC.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $4.98B came in.
  • Fiscal year ended 2025-12-31: from investing, $629.10M went out.
  • Fiscal year ended 2025-12-31: from financing, $3.72B went out.
  • Fiscal year ended 2025-12-31: change in cash, $634.70M came in.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingBuybacksDividendsNew debtStaff share taxNew shares soldOtherNot split outChange in cash
2025-12-31$4.98B-$629.10M-$3.44B-$370.30M-$532.10M$635.90M-$10.30M$634.70M
2024-12-31$4.42B-$2.47B-$2.60B$0.00-$1.03B$1.47B-$33.40M-$248.80M
2023-12-31$4.59B-$3.19B-$2.23B$0.00-$700.60M$1.15B$0.00-$381.60M
2022-12-31$5.01B-$3.78B-$2.08B$0.00-$445.70M$1.52B$0.00$221.30M
2021-12-31$7.08B-$5.38B-$1.65B$0.00-$1.03B$1.67B$690.80M
2020-12-31$2.62B-$70.60M-$5.85B$1.98B-$680.80M$2.58B$577.00M
2019-12-31$2.43B-$2.03B-$275.90M$0.00-$188.00M$211.80M$150.10M
2018-12-31$2.20B-$1.46B-$4.40M$0.00-$187.20M$114.50M$655.00M
2017-12-31$1.31B-$1.01B$0.00-$301.70M$240.20M$0.00$37.10M*$277.50M
2016-12-31$1.49B-$1.05B$0.00-$143.20M$126.70M$0.00-$684.00M*-$261.40M
2015-12-31$1.33B-$907.60M-$160.54M$206.36M$405.32M-$713.93M*$160.38M
2014-12-31$752.43M-$420.78M-$267.58M$126.05M$439.28M-$516.29M*$113.11M
2013-12-31$588.60M-$355.45M-$195.09M$57.39M$211.91M-$2.02M*$305.33M
2012-12-31-$74.61M-$81.07M-$163.30M$63.55M$4.31M-$2.20M*-$253.33M
2011-12-31-$141.68M$128.47M-$25.08M$43.59M$0.00$365.74M*$371.04M
2010-12-31$99.22M-$437.03M-$3.80M$200.59M$46.52M*-$94.50M
2009-12-31-$69.94M-$2.15M$8.60M$22.77M*-$40.72M
2008-12-31-$89.09M$30.82M$7.95M-$200.81M*-$251.13M

Each quarter (3 month)

Quarter endRunning the businessFrom investingBuybacksDividendsDebt paid backNew debtStaff share taxNew shares soldOtherNot split outChange in cash
2026-06-30$813.00M*-$92.70M*-$1.17B*-$96.80M*-$7.60M*$49.20M*$0.00*
2026-03-31$1.08B-$428.90M-$794.30M-$97.80M-$73.20M$163.10M$0.00-$153.10M
2025-12-31$1.17B*$220.30M*-$671.70M*-$92.70M*-$519.20M*$503.50M*$0.00*
2025-09-30$1.62B*-$402.90M*-$664.00M*-$91.20M*-$3.00M*$40.30M*$0.00*
2025-06-30$1.14B*-$1.09B*-$1.06B*-$92.60M*-$5.60M*$31.50M*$0.00*
2025-03-31$1.05B$647.50M-$1.04B-$93.80M-$4.30M$60.60M-$10.30M$604.00M
2024-12-31$1.26B*$350.60M*-$973.00M*$0.00*-$253.40M*$90.90M*$0.00*
2024-09-30$1.29B*-$574.40M*-$735.10M*$0.00*-$120.20M*$254.70M*-$33.40M*
2024-06-30$354.00M*-$557.20M*-$603.90M*$0.00*-$311.80M*$437.60M*$0.00*
2024-03-31$1.51B-$1.69B-$291.30M$0.00-$343.70M$682.10M$0.00-$128.00M
2023-12-31$1.09B*-$66.20M*-$289.00M*-$458.10M*$301.00M*$0.00*
2023-09-30$1.11B*-$496.30M*-$546.50M*-$129.40M*$268.60M*
2023-06-30$1.02B*-$2.39B*-$688.80M*-$16.10M*$90.70M*
2023-03-31$1.37B-$235.70M-$710.70M-$97.00M$485.20M$809.40M
2022-12-31$1.72B*-$1.86B*-$431.10M*-$189.10M*$372.60M*
2022-09-30$628.90M*$192.30M*-$934.60M*-$108.90M*$318.50M*
2022-06-30$564.40M*-$413.90M*-$359.00M*-$48.90M*$306.80M*
2022-03-31$2.10B-$1.71B-$358.10M-$98.80M$521.60M$461.10M
2021-12-31$2.37B*-$2.01B*-$866.90M*$0.00*-$582.40M*$542.70M*
2021-09-30$3.41B*-$2.44B*-$166.40M*-$269.60M*$821.40M*
2021-06-30$626.70M*$125.80M*-$305.20M*-$26.20M*$213.20M*
2021-03-31$668.50M-$1.06B-$306.90M-$154.50M$95.00M-$756.90M
2020-12-31$1.23B*-$305.00M*-$381.10M*$0.00*-$28.30M*$104.10M*
2020-09-30-$254.30M*-$775.80M*-$92.10M*-$80.90M*$303.10M*$481.90M*
2020-06-30$943.40M*$1.45B*-$5.05B*-$416.50M*$1.36B*$1.50B*
2020-03-31$698.00M-$443.20M-$320.70M-$155.10M$811.40M$590.40M
2019-12-31$787.40M*-$208.70M*-$246.50M*$0.00*-$147.50M*$48.30M*
2019-09-30$557.30M*-$207.00M*-$19.40M*$0.00*$8.40M*
2019-06-30$188.30M*-$836.00M*$0.00*-$29.80M*$14.50M*
2019-03-31$897.00M-$776.10M-$10.00M-$10.70M$140.60M$240.80M
2018-12-31$728.80M*-$265.90M*$0.00*-$110.10M*$27.10M*$379.89M*
2018-09-30$452.90M*-$286.70M*-$4.40M*-$45.20M*$53.30M*$169.97M*
2018-06-30$394.60M*-$485.00M*$0.00*-$31.90M*$20.70M*-$101.66M*
2018-03-31$618.80M-$425.40M$0.00$0.00$13.40M$206.80M
2017-12-31$566.94M*-$335.76M*$0.00*-$223.87M*$13.31M*$20.64M*
2017-09-30$414.83M*-$358.88M*-$46.40M*$38.20M*$47.75M*
2017-06-30-$30.57M*-$170.41M*-$31.44M*$172.02M*-$7.06M*-$67.46M*
2017-03-31$355.90M-$140.14M$16.67M$44.14M*$276.57M
2016-12-31$390.38M*-$271.25M*-$96.25M*$36.92M*$0.00*-$432.46M*-$372.66M*
2016-09-30$651.03M*-$405.85M*-$1.94M*$26.17M*$0.00*$4.45M*$273.85M*
2016-06-30$399.50M*-$326.01M*-$43.97M*$24.30M*-$15.65M*$4.12M*$42.29M*
2016-03-31$44.99M-$43.69M-$598.00K-$1.04M$39.30M-$243.86M*-$204.89M
2015-12-31$281.82M*-$123.30M*-$88.86M*$55.94M*$99.77M*-$70.84M*$154.51M*
2015-09-30$892.85M*-$283.17M*-$35.74M*$34.60M*$56.83M*-$401.34M*$264.03M*
2015-06-30$257.83M*-$371.65M*-$14.74M*$39.55M*$78.92M*-$107.27M*-$117.35M*
2015-03-31-$101.73M-$129.48M-$21.19M$76.27M$169.79M-$134.48M*-$140.81M
2014-12-31$198.18M*$56.65M*-$91.72M*$45.24M*$105.13M*-$311.31M*$2.17M*
2014-09-30$164.32M*-$123.07M*-$110.88M*$17.75M*$98.57M*$46.42M*
2014-06-30$336.41M*-$118.12M*-$1.90M*$8.02M*$118.31M*-$204.44M*$138.28M*
2014-03-31$53.53M-$236.23M-$63.09M$55.04M$117.26M-$73.75M
2013-12-31$281.73M*-$109.95M*-$28.73M*$15.68M*$114.07M*$272.40M*
2013-09-30$92.45M*-$214.45M*-$93.22M*$7.42M*$89.96M*-$628.00K*-$118.46M*
2013-06-30$128.16M*$116.63M*-$70.05M*$21.34M*$5.58M*$201.31M*
2013-03-31$86.25M-$147.69M-$3.08M$12.96M$2.29M-$649.00K*-$49.91M
2012-12-31$93.19M*$91.10M*-$91.83M*$15.11M*$3.71M*$111.28M*
2012-09-30-$2.38M*-$48.75M*-$10.03M*$8.81M*-$587.00K*-$52.95M*
2012-06-30-$78.38M*-$139.19M*-$12.37M*$7.80M*-$514.00K*-$222.64M*
2012-03-31-$87.04M$15.77M-$49.08M$31.83M-$500.00K*-$89.03M
2011-12-31-$50.32M*-$33.91M*-$8.76M*$3.45M*$366.75M*$277.21M*
2011-09-30-$46.73M*-$903.00K*-$11.61M*$11.63M*-$47.92M*
2011-06-30-$34.05M*$142.94M*-$3.65M*$14.10M*$118.94M*
2011-03-31-$10.58M$20.35M-$1.06M$14.41M$22.80M
2010-12-31-$40.85M*-$354.62M*$186.83M*-$4.07M*-$212.71M*
2010-09-30$161.50M*$50.17M*$1.70M*$213.29M*
2010-06-30-$11.85M*$3.82M*$2.84M*-$5.31M*
2010-03-31-$9.58M-$136.40M$9.23M$46.99M*-$89.76M
2009-12-31-$44.11M*-$21.46M*$3.97M*$18.36M*-$43.25M*
2009-09-30-$9.82M*-$13.47M*$2.92M*-$773.00K*-$21.14M*

Similar stocks

Stock NameCountryMarket CapPE Ratio
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
BRISTOL MYERS SQUIBB CO (BMY)United States$125.637B12.67
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64
Viatris Inc (VTRS)United States$20.008B-0.00
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07